LEXX - Lexaria Bioscience Corp. News

Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Stu

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexa

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Ag

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regu

Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH

Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing

Lexaria Enters a Material Transfer Agreement with PegBio

Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX)

Lexaria Enters a Material Transfer Agreement With PegBio

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Compa

Lexaria Announces Effective Date for Reverse Stock Split

Kelowna, British Columbia – TheNewswire - July 30, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (t

Lexaria Announces Effective Date for Reverse Stock Split

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar

Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analy

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark

Lexaria Updates Business Development

Kelowna, British Columbia – July 6, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (th

Lexaria Updates Business Development

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company"

Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Tw

Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innova

Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (t

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

Potentially valuable novel compositions being investigated Lexaria also receives additional new gran

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Potentially Valuable Novel Compositions Being Investigated Lexaria Also Receives Additional New Gran

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as t

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as T

12 Health Care Stocks Moving In Monday's After-Market Session

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary Dehydr

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary Dehydr

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Progra

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Progra

Kelowna, British Columbia - June 3 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“

Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglu

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or

Lexaria Bioscience Releases Second Episode of Investor Video Series

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Res

Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lexaria Bioscience Extends Pharma Partnership Through 2026 To Advance GLP-1 Research And DehydraTECH

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innova

Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Anim

Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov

Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhan

Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov

Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analy

12 Health Care Stocks Moving In Thursday's Intraday Session

Lexaria Bioscience To Initiate New, Five-Week Human Clinical Study To Evaluate 2 Oral DehydraTECH-Se

Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov

Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov

12 Health Care Stocks Moving In Friday's After-Market Session

Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Deli

Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS

Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Inj

Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

Lexaria Bioscience Reports Final Phase 1b GLP-1-H24-4 Results Showing DHT-Semaglutide Demonstrates C

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with com